Location of Repository

Association of HIV Diversity and Survival in HIV-Infected Ugandan Infants

By Maria M. James, Lei Wang, Philippa Musoke, Deborah Donnell, Jessica Fogel, William I. Towler, Leila Khaki, Clemensia Nakabiito, J. Brooks Jackson and Susan H. Eshleman
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3077388
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2010). Analysis of HIV diversity using a high resolution melting assay.
    2. (2008). Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.
    3. Antiretroviral Therapy and Medical Management of HIV-infectedChildren (2010) Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://aidsinfonihgov/ContentFiles/PediatricGuidelinespdf: Accessed 9/2/2010.
    4. (2006). Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease.
    5. (2004). Characterization of nevirapine resistance mutations in women with subtype A vs.
    6. (2004). Child mortality and HIV infection in Africa: a review.
    7. (1999). Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.
    8. (1995). Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression.
    9. (1997). Correlation between HIV sequence evolution, specific immune response and clinical outcome in vertically infected infants.
    10. (2008). Deficiency of HIV-Gag-specific T cells in early childhood correlates with poor viral containment.
    11. (1991). Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children.
    12. (1993). Detection of HIV-specific cell-mediated cytotoxicity in the peripheral blood from infected children.
    13. (2006). Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection.
    14. (2003). Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A.
    15. (2008). Dynamic analysis of genetic diversity of gag and env regions of HIV-1 CRF07_BC recombinant in intravenous drug users in Xinjiang Uvghur Autonomous Region, China.
    16. (2008). Early antiretroviral therapy and mortality among HIV-infected infants.
    17. (2008). Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa.
    18. (2006). Evolutionary dynamics of HIV-1 and the control of AIDS.
    19. (2007). Expanded instrument comparison of amplicon DNA melting analysis for mutation scanning and genotyping.
    20. (2000). Gender differences in HIV-1 diversity at time of infection.
    21. (2009). Genetic and antigenic features of the transmitted virus.
    22. (2007). HIV viral diversity and escape from cellular immunity.
    23. (2009). HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response.
    24. (2007). HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads.
    25. (1997). Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease.
    26. (2007). Human immunodeficiency virus-specific CD8+ T-cell activity is detectable from birth in the majority of in utero-infected infants.
    27. (2008). Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
    28. (2009). Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers.
    29. (2010). Identifying and characterizing recently transmitted viruses.
    30. (2002). Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration.
    31. (2003). Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression.
    32. (2003). Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of
    33. (2002). Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_A/G-IbNG infection.
    34. (2005). Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.
    35. (2008). Morbidity and mortality among a cohort of human immunodeficiency virus type 1-infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania. Pediatr Infect Dis
    36. (2005). Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.
    37. (1998). Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline.
    38. (2009). Pediatric HIV-1 in Kenya: pattern and correlates of viral load and association with mortality.
    39. (2009). Response to antiretroviral therapy in HIV-infected Ugandan children exposed and not exposed to single-dose nevirapine at birth.
    40. (2010). Role of humoral immunity in host defense against HIV.
    41. (2007). Selective pressures of human immunodeficiency virus type 1 (HIV-1) during pediatric infection.
    42. (1997). Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS.
    43. (2010). Use of a highresolution melting (HRM) assay to evaluate HIV gag region diversity in HIVinfected adults with different stages
    44. (1997). Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group.
    45. (2002). Virus population homogenization following acute human immunodeficiency virus type 1 infection.
    46. (2010). Wide variation in the multiplicity of HIV-1 infection among injection drug users.
    47. World Health Organization (2008) Scale up of HIV-related prevention, diagnosis, care and treatment for infants and children. http://wwwwhoint/ hiv/pub/paediatric/framework_2008/en/indexhtml: Accessed 12/10/2009.
    48. World Health Organization (2009) Guidelines for HIV diagnosis and monitoring of antiretroviral therapy - Revised version 2009. http:// 2039070117/PDS_DOCS/B4375pdf: Accessed 8/3/2010.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.